Spots Global Cancer Trial Database for Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Study Description

Brief Summary: This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively throughout the peritoneal cavity (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Detailed Description: PRIMARY OBJECTIVE: I. To determine the recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab. SECONDARY OBJECTIVES: I. To describe the pharmacokinetics (PK), toxicities, and immune-related adverse events associated with i.p. checkpoint inhibitor therapy. II. To estimate the clinical benefit rate (rate of partial response \[PR\], complete response \[CR\], and stable disease \[SD\] using Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 modified to include immune-related response criteria) for the expansion cohort. EXPLORATORY OBJECTIVES: I. To determine blood based transcriptional changes associated with pharmacokinetics (PK) time points and determine their correlation with serum drug concentrations, clinical response, and immune related adverse events. II. To determine baseline and on-treatment molecular alteration (ribonucleic acid \[RNA\] and protein) associated with i.p. and nivolumab (Nivo) (for the expansion cohort). OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 groups. GROUP I: Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. GROUP II: Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of the study treatment, patients are followed up every 6 weeks for at least 100 days.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial